NCT04677062 is a NA clinical trial of GV-328 in Aphthous Stomatitis, sponsored by Universitat Internacional de Catalunya.

Who is sponsoring NCT04677062?

NCT04677062 is sponsored by Universitat Internacional de Catalunya.

What drugs are being tested in NCT04677062?

Interventions in NCT04677062: GV-328.

What condition does NCT04677062 study?

NCT04677062 studies Aphthous Stomatitis.

Is NCT04677062 still recruiting?

NCT04677062 is currently completed. Last updated 1 February 2021.

Last reviewed 2021-02-01 · How we verify

NCT04677062

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Galenic Acceptability and Efficacy of GV-328 Lozenges in Children With Oral Aphthosis

Completed NA Last updated 1 February 2021

What this trial tests

NA trial testing GV-328 in Aphthous Stomatitis in 33 participants. Completed in 30 June 2019.

Timeline

1 November 2017

Primary endpoint
30 June 2019

30 June 2019

Quick facts

Lead sponsor	Universitat Internacional de Catalunya
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	1 November 2017
Primary completion	30 June 2019
Estimated completion	30 June 2019
Sites	1 location across Spain

Drugs / interventions tested

GV-328 — full drug profile →

Conditions studied

Aphthous Stomatitis — all drugs for Aphthous Stomatitis →

Sponsor

Universitat Internacional de Catalunya — full company profile →

Who can join

Adults 3 to 13, any sex, with Aphthous Stomatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study was to assess the safety, acceptability, and efficacy of product GV-328 for the treatment of childhood oral aphthous lesion.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

[Safety, galenic acceptability and efficacy of GV-328 lozenges in children with oral aphthosis].
Guinot Jimeno F, Fernández Sencion JN, Giner Tarrida L, Veloso Durán A. · · 2022 · PMID 35228071 · DOI 10.1016/j.aprim.2022.102311

Verify or expand the search:

Other Universitat Internacional de Catalunya trials

Trials by the same sponsor.

NCT07478159 — Maternal Musculoskeletal Factors of the Hip, Lumbopelvic, Abdominal and Pelvic Floor Regions and Their Association With · not yet recruiting
NCT07415486 — Immediate Implants in Front Teeth With Bone Loss: Regeneration and Temporary Crown in a Randomized Clinical Study · NA · not yet recruiting
NCT07405541 — Knowledge of Periodontitis and Its Relation to Periodontal Health · not yet recruiting
NCT07417293 — Clinical and Patient Outcomes of 4 mm Ultra-Short vs. 8 mm Implants With Bone Augmentation in the Back Upper Jaw · NA · not yet recruiting
NCT07329244 — Graphene-Reinforced CAD/CAM Restorations for MIH-Affected Molars in Adolescents: A Prospective Clinical Study · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04677062 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universitat Internacional de Catalunya
Last refreshed: 1 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04677062.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing